About half of all melanomas have mutations in the BRAFÂ gene that accelerate tumor cell growth and spread. While most patients benefit from targeted anti-BRAFÂ therapy, resistance to treatment and tumor progression is almost ...
Apr 12, 2018
0
2
Mutations in human epidermal growth factor receptor 2 (HER2) were found to confer resistance to hormone therapy in some estrogen receptor (ER)-positive metastatic breast cancer cases, and resistance could be reversed by dual ...
Mar 19, 2018
0
8
A Virginia Tech Carilion Research Institute team has identified a new therapeutic target to treat glioblastoma, the most devastating and common form of brain cancer.
Jan 31, 2018
0
134
In animal experiments, a human-derived glioblastoma significantly regressed when treated with the combination of an experimental enzyme inhibitor and the standard glioblastoma chemotherapy drug, temozolomide.
Jan 23, 2018
0
7
Lung cancer is the leading cause of cancer-associated deaths. One of the most promising ways to treat it is by immunotherapy, a strategy that turns the patient's immune system against the tumor. In the past twenty years, ...
Dec 12, 2017
0
120
It's just one step. Flushing the bladder with a common chemotherapy drug after a cancerous tumor is surgically removed reduces the chances of that cancer returning. Canadian and European clinical trials have proven this true ...
May 15, 2017
0
0
Japanese researchers identify process to improve fluorescence detection of cancer stem cells, which are primarily responsible for brain tumor progression and recurrence after treatment
Mar 30, 2017
0
2
UCLA researchers have discovered that combining a vaccine developed at UCLA with other experimental therapies and FDA-approved treatments shows promise for reducing the size of advanced brain tumors. The immunotherapy, which ...
Jan 25, 2017
0
2
Administering chemotherapy to African-American breast cancer patients prior to surgery could improve their prognosis and survival rates from the disease, according to a new study.
Jan 19, 2017
0
1
Radiomics, an approach that combines imaging and computation, can stratify patients with recurrent glioblastoma into those who are likely to benefit from the antiangiogenic therapy bevacizumab (Avastin) and those who do not, ...
Oct 11, 2016
0
1
